Kiniksa Pharmaceuticals International, plc

Good morning and welcome to the Conixa Pharmaceuticals second quarter 2022 financial earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press the star one again. For operator assistance throughout the call, please press star zero. And finally, I would like to advise all participants that this call is being recorded. Thank you. I would now like to hand over to Rachel Frank, head of IR.

Thank you, operator. Good morning, everyone, and thank you for joining Connexa's call to discuss our second quarter 2022 financial results and corporate update. The press release highlighting these results can be found on our website under the Investors and Media section. As for the agenda, our CEO, Sanj K. Patel, will start with an introduction. Then, Eben Tesari, our Chief Operating Officer, will review our global license agreement with Genentech for the right to develop and commercialize this Darilla map, which we announced this morning. Ross Mote, our Chief Commercial Officer, will provide an update on our Arculus commercial execution. And then, Mark Ragosa, our Chief Financial Officer, will review our second quarter 2022 financial results. And finally, Sandhya will return for closing remarks and to kick off the Q&A session, for which John Paolini, our Chief Medical Officer, will also be on the line. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements except as required by law. With that, I will turn it over to Sanj.

Thanks, Rachel, and good morning, everyone. I am really excited today to talk to you about two key updates.